Compare Novo Nordisk A/S (NVO) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Rush Street Interactive Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Rush Street Interactive Inc trades at $33.46 (market cap $3.55B). The key difference: Novo Nordisk A/S is far larger — about 62.1× Rush Street Interactive Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals.
| NVO | RSI | |
|---|---|---|
Market Cap | $220.53B | $3.55B |
Sector | Health | Technology |
52-Week High | $71.70 | $34.52 |
52-Week Low | $35.29 | $14.55 |
Enterprise Value | $239.49B | $3.23B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Rush Street Interactive (RSI) trades at $34.52, up 6.22% in 24 hours, with strong bullish momentum from technical indicators and recent earnings beats. The stock shows robust revenue growth, reaching $1.13B in 2025, and maintains a 76.92% buy rating from analysts. Positive sentiment is fueled by expansion news, such as the BetRivers launch in Alberta (GlobeNewsWire, 2026-07-13).
Outlook remains positive with earnings growth as a key catalyst, though high valuation multiples (P/E 101.53) and overbought RSI levels pose risks. The consensus price target of $31.11 suggests potential downside, but institutional bullishness and operational cash flow strength support long-term upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
